304360 — S Biomedics Co Income Statement
0.000.00%
Last trade - 00:00- KR₩267bn
- KR₩268bn
- KR₩14bn
Annual income statement for S Biomedics Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | — | — | — | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 5,319 | 8,868 | 12,113 | 13,108 | 13,734 |
| Cost of Revenue | |||||
| Gross Profit | 1,298 | 4,319 | 6,111 | 6,554 | 6,707 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 13,752 | 13,474 | 15,856 | 19,062 | 19,010 |
| Operating Profit | -8,433 | -4,606 | -3,744 | -5,954 | -5,276 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -8,594 | -5,249 | -5,210 | -6,337 | -5,757 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -8,590 | -5,242 | -4,755 | -6,460 | -5,821 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -7,747 | -5,667 | -6,327 | -7,524 | -5,821 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -7,747 | -5,667 | -6,327 | -7,524 | -5,821 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -705 | -517 | -576 | -691 | -516 |
| Dividends per Share |